• 1
    De Giorgio R, Barbara G, Stanghellini V et al. Diagnosis and therapy of irritable bowel syndrome. Aliment Pharmacol Ther 2004; 20: 1022.
  • 2
    Rolfe RD. The role of probiotic cultures in the control of gastrointestinal health. J Nutr 2000; 130: 396S402S.
  • 3
    de Roos NM, Katan MB. Effects of probiotic bacteria on diarrhea, lipid metabolism, and carcinogenesis: a review of papers published between 1988 and 1998. Am J Clin Nutr 2000; 71: 40511.
  • 4
    Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361: 5129.
  • 5
    Bengmark S. Ecological control of the gastrointestinal tract. The role of probiotic flora. Gut 1998; 42: 27.
  • 6
    Saggioro A. Probiotics in the treatment of irritable bowel syndrome. J Clin Gastroenterol 2004; 38: S1046.
  • 7
    Shanahan F. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease. Am J Physiol 2005; 288: G41721.
  • 8
    Mimura T, Rizello F, Helwig U et al. Once daily high dose probiotic therapy (VSL# 3) for maintaining remission in recurrent or refractory pouchitis. Gut 2004; 53: 10814.
  • 9
    Gionchetti P, Rizzello F, Helwig U et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 2003; 124: 12029.
  • 10
    Nobaek S, Johansson ML, Molin G, Ahrne S, Jeppsson B. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000; 95: 12318.
    Direct Link:
  • 11
    Kim HJ, Camilleri M, McKinzie S et al. A randomized controlled trial of a probiotic, VSL# 3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 2003; 17: 895904.
  • 12
    O'Mahony L, McCarthy J, Kelly P et al. A randomized, placebo-controlled, double-blind comparison of the probiotic bacteria Lactobacillus and Bifidobacterium in irritable bowel syndrome (IBS): symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128: 54151.
  • 13
    Kamath PS, Phillips SF, O'Connor MK, Brown ML, Zinsmeister AR. Colonic capacitance and transit in man: modulation by luminal contents and drugs. Gut 1990; 31: 4439.
  • 14
    Binder HJ, Mehta P. Short-chain fatty acids stimulate active sodium and chloride absorption in vitro in the rat distal colon. Gastroenterology 1989; 96: 98996.
  • 15
    Talley NJ, Phillips SF, Wiltgen CM, Zinsmeister AR, Melton LJ 3rd. Assessment of functional gastrointestinal disease: the bowel disease questionnaire. Mayo Clin Proc 1990; 65: 145679.
  • 16
    del Campo R, Bravo D, Canton R et al. Scarce evidence of yogurt lactic acid bacteria in human feces after daily yogurt consumption by healthy volunteers. Appl Environ Microbiol 2005; 71: 5479.
  • 17
    Brigidi P, Swennen E, Vitali B, Rossi M, Matteuzzi D. PCR detection of Bifidobacterium strains and Streptococcus thermophilus in feces of human subjects after oral bacteriotherapy and yogurt consumption. Int J Food Microbiol 2003; 81: 2039.
  • 18
    Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastroenterol 1997; 32: 9204.
  • 19
    Heaton KW, Radvan J, Cripps H, Mountford RA, Braddon FE, Hughes AO. Defecation frequency and timing, and stool form in the general population: a prospective study. Gut 1992; 33: 81824.
  • 20
    Heaton KW, O'Donnell LJ. An office guide to whole-gut transit time. Patients’ recollection of their stool form. J Clin Gastroenterol 1994; 19: 2830.
  • 21
    Heaton KW, Gosh S, Braddon FE. How bad are the symptoms and bowel dysfunction of patients with the irritable bowel syndrome? A prospective, controlled study with emphasis on stool form. Gut 1991; 32: 739.
  • 22
    Coulie B, Szarka LA, Camilleri M et al. Recombinant human neurotrophic factors accelerate colonic transit and relieve constipation in humans. Gastroenterology 2000; 119: 4150.
  • 23
    Proano M, Camilleri M, Phillips SF, Brown ML, Thomforde GM. Transit of solids through the human colon: regional quantification in the unprepared bowel. Am J Physiol 1990; 258: G85662.
  • 24
    Camilleri M, Zinsmeister AR. Towards a relatively inexpensive, noninvasive, accurate test for colonic motility disorders. Gastroenterology 1992; 103: 3642.
  • 25
    Burton DD, Camilleri M, Mullan BP, Forstrom LA, Hung JC. Colonic transit scintigraphy labeled activated charcoal compared with ion exchange pellets. J Nucl Med 1997; 38: 180710.
  • 26
    Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel function in female irritable bowel patients with alosetron, a 5-HT3 receptor antagonist. Aliment Pharmacol Ther 1999; 13: 114959.
  • 27
    Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW. Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000; 355: 103540.
  • 28
    Cremonini F, Mullan BP, Camilleri M et al. Performance characteristics of scintigraphic transit measurements for studies of experimental therapies. Aliment Pharmacol Ther 2002; 16: 178190.
  • 29
    Ma D, Forsythe P, Bienenstock J. Live Lactobacillus reuteri is essential for the inhibitory effect on tumor necrosis alpha-induced interleukin-8 expression. Infect Immun 2004; 72: 530814.
  • 30
    Borruel N, Carol M, Casellas F et al. Increased mucosal tumor necrosis factor α production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002; 51: 65964.
  • 31
    Pathmakanthan S, Li C, Cowie J, Hawkey CJ. Lactobacillus plantarum 299: beneficial in vitro immunomodulation in cells extracted from inflamed human colon. J Gastroenterol Hepatol 2004; 19: 16673.
  • 32
    Borruel N, Casellas F, Antolin M et al. Effects of nonpathogenic bacteria on cytokine secretion by human intestinal mucosa. Am J Gastroenterol 2003; 98: 86570.
    Direct Link:
  • 33
    McCarthy J, O'Mahony L, O'Callaghan L et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance. Gut 2003; 52: 97580.
  • 34
    Menard S, Candalh C, Bambou JC et al. Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport. Gut 2004; 53: 8218.
  • 35
    Madsen K, Cornish A, Soper P et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 58091.
  • 36
    Cremonini F, Di Caro S, Nista EC et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther 2002; 16: 14617.
  • 37
    Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology 2004; 126: 162033.
  • 38
    Pimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 4129.
  • 39
    Malinen E, Rinttila T, Kajander K et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 37382.
    Direct Link:
  • 40
    Tanaka H, Hashiba H, Kok J, Mierau I. Bile salt hydrolase of Bifidobacterium longum– biochemical and genetic characterization. Appl Environ Microbiol 2000; 66: 250212.
  • 41
    Tannock G, Dashkevicz MP, Feighner SD. Lactobacilli and bile salt hydrolase in the murine intestinal tract. Appl Environ Microbiol 1989; 55: 184851.
  • 42
    Moser SA, Savage DC. Bile salt hydrolase activity and resistance to toxicity of conjugated bile salts are unrelated properties in lactobacilli. Appl Environ Microbiol 2001; 67: 347680.
  • 43
    Kurdi P, Tanaka H, van Veen HW et al. Cholic acid accumulation and its diminution by short-chain fatty acids in Bifidobacteria. Microbiology 2003; 149: 20317.
  • 44
    Tanaka H, Doesburg K, Iwasaki T, Mierau I. Screening of lactic acid bacteria for bile salt hydrolase activity. J Dairy Sci 1999; 82: 25305.
  • 45
    Brydon WG, Nyhlin H, Eastwood MA, Merrick MV. Serum 7 alpha-hydroxy-4-cholesten-3-one and selenohomocholyltaurine (SeHCAT) whole body retention in the assessment of bile acid induced diarrhea. Eur J Gastroenterol Hepatol 1996; 8: 11723.
  • 46
    Chadwick VS, Gaginella TS, Carlson GL et al. Effect of molecular structure on bile acid-induced alterations in absorptive function, permeability, and morphology in the perfused rabbit colon. J Lab Clin Med 1979; 94: 66174.
  • 47
    Bazzocchi G, Gionchetti P, Almerigi PF et al. Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome. Digest Liver Dis 2002; 34: S4853.
  • 48
    Verdu EF, Bercik P, Bergonzelli G et al. Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction. Gastroenterology 2004; 127: 82637.